The combination of heparin 5000 U and dihydroergotamine 0.5 mg (HDHE) was marketed in the U.S. in 1985 for prophylaxis of postoperative deep venous thrombosis (DVT). This article evaluates the efficacy, safety, and cost of HDHE for abdominal, pelvic, thoracic, and total hip surgical prophylaxis. Although several controlled trials comparing HDHE to minidose heparin (MDH) indicate superior efficacy of HDHE for nonorthopedic surgical procedures, others do not. Differences in study design and insufficient sample sizes may account for the dichotomy. In the U.S. Multicenter Trial, MDH was surprisingly ineffective for preventing radiofibrinogen uptake test-proven DVT. The apparent superiority of HDHE over MDH is therefore questionable. Ergot-related side effects have been minimized in all studies due to careful patient selection. In actual use, the potential for such side effects appears to be increased. Because twice-daily HDHE is no more effective, costs 4–11 times more, and may pose a greater risk than MDH, the authors do not recommend its use for general surgical prophylaxis. HDHE may prove to be useful in patients undergoing total hip replacement.
HullRD, RaskobGE, HirshJ. Prophylaxis of venous thromboembolism.Chest1986; 89(suppl): 374S–83S.
6.
PetersonCW. Venous thrombosis: an overview.Pharmacotherapy1986; 6(4 Pt 2): 12S–7S.
7.
KoppenhagenK, WiechmannA, ZuhlkeHV, WenigHG, HaringR. Effectiveness and risk of thromboembolism prophylaxis in surgery (translated).Therapiewoche1979; 29: 5920–6.
8.
KunzS, BrielRC, KrahneA. The thrombosis risk after abdominal and vaginal hysterectomy (translated).Geburtshilfe Frauenheilkd1979; 39: 932–9.
9.
KaiserD, StreyM, HauH. Optimized thromboembolism prophylaxis in thoracic surgery controlled studies with heparin-dihydergot (translated).Krankenhausarzt1981; 54: 692–8.
10.
BruckeP, DienstlE, VinazzerH, SimmaW. Prophylaxis of postoperative thromboembolism: low dose heparin vs. heparin dihydroergotamine.Thromb Res1983; 29: 377–82.
11.
Wille-JorgensenP, KjaergaardJ, ThorupJ. Heparin with and without dihydroergotamine in prevention of thromboembolic complications of major abdominal surgery.Arch Surg1983; 118: 926–8.
12.
PedersenB, ChristiansenJ. Thromboembolic prophylaxis with dihydroergotamine-heparin in abdominal surgery.Am J Surg1983; 145: 788–90.
13.
VethG, MeuwissenOJA, Van HouwelingenHC, SixmaJJ. Prevention of postoperative deep vein thrombosis by a combination of subcutaneous heparin with subcutaneous dihydroergotamine or oral sulphinpyrazone.Thromb Haemost1985; 54: 570–3.
14.
AdolfJ, ButtermannG, WeidenbachA, GmeinederF. Optimierung der Postoperativen Thromboseprophylaxe in der Gynakologie (translated abstract).Geburtshilfe Frauenheilkd1978; 38: 98–104.
15.
KoppenhagenK, HÄRINGR, ZuhlkeHV, WiechmannA, WenigHG. Efficiency and risk of thromboembolism prophylaxis in surgery. Clinico-experimental results in 1434 general surgery patients (abstract).Thromb Haemost1979; 4: 249.
16.
MoserG. Prevention of deep venous thrombosis (translated abstract).Ther Umsch1980; 37: 118–21.
17.
ButtermannG, HaluszczynskiI, TheisingerW, PabstHW. Postoperative Thromboembolie-prophylaxe mit reduziertem low-dose Heparin-anteil und Dihydroergotamin in fixer kombination.Munch Med Wschr1981; 123: 1213–6. (translated abstract only)
18.
KoppenhagenK, HÄRINGR. Comparative study between heparin-dihydergot 2500 and low dose heparin (translated).Klinikarzt1981; 10: 782–6.
19.
KoppenhagenK, HÄRINGR. Thromboembolism prophylaxis with reduced hemorrhagic risk. Studies with heparin-dihydergot 2500(translated).Med Wlt1981; 32: 1021–2.
20.
BreddinK, HÄRINGR, KoppenhagenK. Prâvention postoperativer Thrombotischer Komplikationen mit Heparin und Dihydroergotamin (translated abstract).Deutsch Med Wschr1983; 108: 98–102.
21.
AmmannJF, AebiB. The risk of hemorrhaging in the prevention of thromboembolism in general surgery: comparison of low-dose heparin and heparin-dihydergot 2500 (translated abstract).Chirurg1983; 54: 29–32.
22.
Gentm, RobertsRS. A meta-analysis of the studies of dihydroergotamine plus heparin in the prophylaxis of deep vein thrombosis.Chest1986; 89: 396S–400S.
23.
GoldmanL, FeinsteinAR. Anticoagulants and myocardial infarction. The problems of pooling, drowning, and floating.Ann Intern Med1979; 90: 92–4.
CoveyTH, ShermanL, BaueAE. Low dose heparin in postoperative patients. A prospective, coded study.Arch Surg1975; 110: 1021–6.
26.
Food and Drug Administration.Draft guideline for the format and content of the clinical data section of an application.Rockville, MD: Center for Drugs and Biologics, 1986. Docket no. 85-D-0467,21.
27.
MonrealM, FozM, UbiernaMT, SolerJM, SalazarJ, CajaV. Skin and muscle necrosis during heparin-dihydroergotamine prophylaxis (letter).Lancet1984; 2: 820.
28.
CunninghamM, De TorrenteA, EkoeJM, AckermannJP, HumairL. Vascular spasm and gangrene during heparin-dihydroergotamine prophylaxis.Br J Surg1984; 71: 829–31.
29.
ComerotaAJ, WhiteJV. The use of dihydroergotamine and heparin in the prophylaxis of deep venous thrombosis.Chest1986; 89: 389S–95S.
30.
GattererR. Ergotism as complication of thromboembolic prophylaxis with heparin and dihydroergotamine (letter).Lancet1986; 2: 638–9.
31.
StamatakisJD, KakkarVV, SagarS, LawrenceD, NairnD, BentleyPG. Femoral vein thrombosis and total hip replacement.Br Med J1977; 2: 223–5.
32.
FredinHO, RosbergB, ArboreliusM, NylanderG. On thromboembolism after total hip replacement in epidural analgesia: a controlled study of dextran 70 and low-dose heparin combined with dihydroergotamine.Br J Surg1984; 71: 58–60.
33.
KakkarVV, FokPJ, MurrayWJG, PaesT, MerensteinD, DoddsR. Heparin and dihydroergotamine prophylaxis against thromboembolism after hip arthroplasty.J Bone Joint Surg (Br)1985; 67-B: 538–42.
34.
ComerotaAJ, DiserioFJ, SasaharaAA. Dihydroergotamineheparin prophylaxis of DVT in total hip replacement patients; a multicenter trial. Proceedings of the International Society of Thrombosis Hemostasis, San Diego, July 14–19, 1985.
35.
Drug topics: annual pharmacists' reference (red book).Oradell, NJ: Medical Economics Company, Inc.,1986.
